What Is the Treatment of Leriche Syndrome with Intermittent Claudication and No Rest Pain?
This protocol addresses patients with symptomatic peripheral arterial disease presenting with intermittent claudication. There is no rest pain, no nonhealing wounds, no acute limb ischemia, and no chronic limb-threatening ischemia — placing the patient in a stage where conservative, structured medical management is the priority.
The characteristic picture is claudication triggered by walking and relieved by rest, without evidence of advanced limb compromise. Initial management at this stage targets both cardiovascular risk reduction and meaningful improvement in walking capacity.
The structured regimen for this presentation includes antiplatelet therapy, pharmacological support specifically aimed at improving walking distance, and comprehensive best medical management — together with a supervised exercise programme. The complete drug selection, sequencing, and all clinical parameters are available in the full protocol.
Improvement in walking distance.
References
DOI: 10.1016/j.jacr.2025.02.024
- For initial management of any patient without lifestyle-limiting claudication or evidence of rest pain or nonhealing wounds, it is recommended that antiplatelet adjunctive therapy be initiated.
- Severe claudication without rest pain.
- Use of acetylsalicylic acid (ASA) alone (range 75-325 mg per day) is recommended in all patients with symptomatic PAD to reduce the risk of major adverse cardiac event (MACE).
- In addition, there is strong evidence indicating cilostazol as an effective therapy to improve walking distance in patients with IC.
- High-dose statin therapy is indicated if tolerated (class IA).
- Antihypertensive therapy should be administered to all patients with HTN and PAD to reduce the risk of MACE including stroke, MI, heart failure, or CV death.
- Patients with IC should also be prescribed supervised exercise therapy (SET) if possible.